Ignite Creation Date:
2024-05-05 @ 11:40 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00109564
Status:
COMPLETED
Last Update Posted:
2008-07-18
First Post:
2005-04-28
Brief Title:
A Safety and Efficacy Study of Ispronicline TC-1734-112 in Subjects With Age Associated Memory Impairment AAMI
Sponsor:
Targacept Inc
Organization:
Targacept Inc
Study Overview
Official Title:
A Safety and Efficacy Study of TC-1734-112 in Subjects With Age Associated Memory Impairment AAMI
Status:
COMPLETED
Status Verified Date:
2008-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this Phase II study is to evaluate the efficacy and safety of ispronicline TC-1734-112 compared to placebo inactive substance pill in patients with age associated memory impairment AAMI AAMI is characterized as cognitive impairment including memory loss and poor concentration associated with aging
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None